Gabather AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GABA.ST research report →
Companywww.gabather.com
Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was incorporated in 2014 and is based in Södertälje Sweden.
- CEO
- Michael-Robin Witt
- IPO
- 2014
- Employees
- 3
- HQ
- Södertälje, SE
Price Chart
Valuation
- Market Cap
- $10.39M
- P/E
- -2.08
- P/S
- 0.00
- P/B
- -10.98
- EV/EBITDA
- -1.76
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 446.23%
- ROIC
- 512.98%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-4,652,000 · 40.00%
- EPS
- $-0.02 · 93.46%
- Op Income
- $-4,526,000
- FCF YoY
- -117.07%
Performance & Tape
- 52W High
- $0.13
- 52W Low
- $0.02
- 50D MA
- $0.04
- 200D MA
- $0.04
- Beta
- -0.71
- Avg Volume
- 5.08M
Get TickerSpark's AI analysis on GABA.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our GABA.ST Coverage
We haven't published any research on GABA.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GABA.ST Report →